T-Scores in a 34-Year-Old Man After a Fragility Fracture
A 34-year-old man is referred for DXA after a distal radius fracture sustained in a fall while stepping off a curb. He is 180 cm, 74 kg, a nonsmoker, takes no medications, and reports no chronic illness. The scanner printout lists: L1–L4 BMD 0.760 g/cm², T −2.8, Z −2.3; femoral neck BMD 0.660 g/cm², T −2.6, Z −2.1; total hip T −2.3, Z −1.9. The referring physician reads only the T-scores and tells the patient he has osteoporosis and should start alendronate. The patient, who is clearly alarmed, asks the technologist to explain the numbers and whether he really needs the drug. No secondary-cause workup has been ordered: no testosterone, TSH, celiac serology, 24-hour urine calcium, SPEP, or glucocorticoid history.
1. Which number on this report should drive interpretation in this patient, and why?
Read the worked answer
The Z-score, not the T-score.
The T-score compares the patient to a young-adult reference population and was designed to classify postmenopausal women and men aged 50 and older, where low bone mass reflects age-related loss and predicts fracture in that population. This patient is 34; his expected BMD is close to peak bone mass, so the T-score and Z-score diverge mostly because of reference-database differences, not biology. There is also a technical trap: some manufacturers compute male T-scores against a female reference, which makes the T-score even less meaningful in a young man.
ISCD guidance is that Z-scores should be used in premenopausal women and in men under 50. His lowest Z-score is −2.3 at the lumbar spine. A Z-score of −2.0 or below is termed "below the expected range for age" - that phrasing, not "osteoporosis," is what belongs on the report. The T-scores may be printed by the software, but they should not be the basis of a diagnosis or a drug decision in this patient.
2. Does this DXA study establish a diagnosis of osteoporosis? What should the report actually say?
Read the worked answer
No - not by densitometry alone.
ISCD position: in men under 50 and in premenopausal women, bone densitometry alone should not be used to diagnose osteoporosis. The WHO T-score thresholds were derived and validated in older populations and do not transfer to a 34-year-old man. The DXA report should state the Z-score with its age-, sex-, and ethnicity-matched reference, describe the result as "below the expected range for age," and recommend evaluation for secondary causes. It may note the fragility fracture as a clinical finding but should not convert it into a densitometric diagnosis.
A clinician may legitimately diagnose osteoporosis in a young man when a fragility fracture is combined with low bone mass and other causes are excluded - but that is a clinical diagnosis made by the treating physician after workup, not a category the technologist assigns from a T-score. Keeping that distinction clean protects the patient from being labeled - and treated - on the wrong number.
3. The patient asks whether he needs alendronate. How do you answer within your scope?
Read the worked answer
Explain the findings, do not prescribe or deprescribe, and route the decision back to the physician.
What is appropriate to say: the scan shows bone density lower than expected for a man his age; the T-score his physician quoted is not the right number for someone his age; a low-trauma fracture at 34 is unusual and deserves a search for an underlying cause before committing to long-term drug therapy.
What to emphasize about the workup: in young men with fragility fractures, an identifiable secondary cause is common - hypogonadism, glucocorticoid exposure, hyperparathyroidism, celiac disease, inflammatory bowel disease, multiple myeloma, alcohol use, low body weight, anticonvulsants, and others. Testosterone, TSH, celiac serology, 24-hour urine calcium, SPEP, and a medication review are standard elements.
What to avoid: telling the patient he does or does not need alendronate, or that he should stop a medication a physician recommended. Also avoid implying the DXA is "normal" - it is not. If monitoring is planned, note that follow-up should be on the same densitometer so changes can be interpreted.